BioLineRx (NASDAQ: BLRX) announced today positive pre-clinical results for BL-8040 in a third indication - as a treatment for chronic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE